100% secure customs clearance, high-quality Tofacitinib CAS 477600-75-2, and the most favorable price
1 Inquiries
477600-75-2
Pharmaceutical Grade
99%
shanghai
1kg/bag;25kg/Cardboard Drum
2026-02-26
Estradiol,Progesterone,GS441524,4-Butylresorcinol,DeoxyArbutin,Coenzyme Q10
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceTofacitinib is a JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively.
Tofacitinib is a pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor and an antirheumatic drug. It is a pyrrolopyrimidine, a N-acylpiperidine, a nitrile and a tertiary amino compound.|Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.|Tofacitinib is a Janus Kinase Inhibitor. The mechanism of action of tofacitinib is as a Janus Kinase Inhibitor.|Tofacitinib is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease. Tofacitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy, but has yet to be linked to cases of clinically apparent acute liver injury.|Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis and in late 2020 was given emergency use authorization as therapy in combination with remdesivir for severe COVID-19. Baricitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury.|Tofacitinib is an orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.Basic Info-
Product Name:
Tofacitinib
Other Name:1-Piperidinepropanenitrile,4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-,(3R,4R)-;3-Piperidinamine,1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-,(3R,4R)-;(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile;CP 690550;Tofacitinib;2097815-04-6
CAS No.:477600-75-2
Molecular Formula:C16H20N6O
InChIKeys:InChIKey=UJLAWZDWDVHWOW-YPMHNXCESA-N
Molecular Weight:312.3696
Exact Mass:312.37
EC Number:1806241-263-5
UNII:87LA6FU830
DSSTox ID:DTXSID90197271
NCI Thesaurus Code:C95800
Color/Form:Yellow foam
ATC Code:L04AA29|L - Antineoplastic and immunomodulating agents
HScode:29335990
Categories:
Characteristics-
PSA:
88.9
XLogP3:1.5
Density:1.3±0.1 g/cm3
Melting Point:White crystalline solid. MP: 199-206 °C /Tofacitinib monocitrate/
Boiling Point:585.845ºC at 760 mmHg
Flash Point:308.1±30.1 °C
Refractive Index:1.646
Water Solubility:In water, 155.1 mg/L at 25 deg C (est)
Storage Conditions:Keep container tightly closed in a dry and well-ventilated place. /Tofacitinib citrate/
Vapor Pressure:1.32X10-10 mm Hg at 25 deg C (est)
Specific rotation:Specific optical rotation: +10.4 deg at 25 °C/D (c = 0.64 in methanol)
Henrys Law Constant:Henry's Law constant = 3.17X10-21 atm-cu m/mol at 25 °C (est)
Dissociation Constants:pKa1 = 8.46 (cyano); pKa2 = 13.56 (secondary amine)
Experimental Properties:Hydroxyl radical reaction rate constant = 2.57X10-10 cu cm/molec-sec at 25 °C (est)
Hazard IdentificationClassification of the substance or mixture
Not classified.
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H301 Toxic if swallowed
H311 Toxic in contact with skin
H315 Causes skin irritation
H319 Causes serious eye irritation
H331 Toxic if inhaled
H335 May cause respiratory irritation
Precautionary statement(s) Prevention none
Response none
Storage none
Disposal none
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Estradiol,Progesterone,GS441524,4-Butylresorcinol,DeoxyArbutin,Coenzyme Q10
-
Location:
XINYUAN DADUHUI PHASE 1, NO.258 TAOYUAN NORTH ROAD, LIANHU DISTRICT, XI 'AN , SHAANXI CHINA
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
30
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2023
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
Canada
Tofacitinib
10 G Nov 28, 2025 Post an enquiry for this product
